Showing results (161-170 of 192) with videos related to
Sort By:
Pageof 20
Eclinicalmedicine|October 28, 2025
Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trialYuxiang Ma, Zhengbo Song, Jianhua Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.Nature Medicine|April 29, 2025
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trialByoung Chul Cho, Shun Lu, Myung Ah Lee, et al.Therapeutic Advances in Medical Oncology|October 1, 2025
Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter studyShengjie Yang, Yue Hao, Ke Wang, et al.Annals of Translational Medicine|October 21, 2022
Impact of individualized pharmaceutical care on efficacy and safety of opioid-tolerant outpatients with cancer pain: a multicenter randomized controlled trialHaiying Ding, Yu Song, Nan Wu, et al.Nature Communications|June 12, 2023
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancerShen Zhao, Wu Zhuang, Baohui Han, et al.The Lancet. Oncology|February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyZiming Li, Yan Wang, Yuping Sun, et al.Patterns (New York, N.Y.)|March 5, 2025
SplitFusion enables ultrasensitive gene fusion detection and reveals fusion variant-associated tumor heterogeneityWeiwei Bian, Baifeng Zhang, Zhengbo Song, et al.Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.Pageof 20